跳至主要内容
临床试验/CTRI/2024/03/064841
CTRI/2024/03/064841尚未招募2 期

Randomized, open-label, pilot clinical trial to evaluate the efficacy of Saindhavadi Anjana in Meibomian Gland Dysfunction (MGD) associated Dry Eye Disease (DED) - Nil

one0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
one

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Signed ICF (Informed Consent Form)
  • Patients presenting with signs and symptoms of Shushkakshipaka
  • Patients presenting with signs of MGD
  • Ocular dryness
  • Meibomian gland orifice plugging
  • Lid margin telangiectasia
  • TBUT less than 5 seconds
  • Schirmer’s test less than 10mm

排除标准

  • Cases complicated with acute, chronic, infective conjunctivitis or any specific eyelid disorder, corneal ulcer, dacryocystitis and lagophthalmos
  • Inflammatory diseases unrelated to MGD
  • Patients suffering from any systemic disorder or taking any medications which in the
  • opinion of PI may affect the clinical outcome of the trial
  • Contact lenses use
  • History of ocular surgery within 6 months prior to enrolment in trial
  • Pregnancy or child bearing age without contraception
  • Stevens-Johnson syndrome
  • Chemical, thermal or radiation injury
  • Sjogren’s syndrome
  • Patient who starts developing complications will be excluded from the study
  • Patient not willing for the treatment
  • Ongoing ocular or systemic infection
  • Ocular or periocular malignancy
  • Use of topical steroids, topical cyclosporine, topical anti-glaucoma medication within 60 days before screening
  • Lid structural abnormality not caused by MGD

研究者

发起方
one

相似试验

Effect of Saindhavadi Anjana in Dry Eye Disease | 临床试验